Oximum

Sildenafil

Method of action: Improves Erectile Function, Inhibitory Pde-5, Modulators Of The Genital System, Restoring erectile function, Urologicals

Treatment option: Impotence, Heart Disease, Congenital Heart Disease, Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Sexual Dysfunction, Male

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oximum

What is Oximum? (Sildenafil Citrate)

Oximum is a prescription-only pharmaceutical preparation identified by its active ingredient, Sildenafil Citrate. This medicine belongs to the highly specific pharmacological class known as Selective Phosphodiesterase Type 5 (PDE5) Inhibitors, signifying its targeted action within the body's vascular system.

Quick Facts

Property	Description
Active ingredient	Sildenafil Citrate
Form	Oral film-coated tablets
Pharmacological class	Selective PDE5 Inhibitor
Origin	Synthetic compound

Oximum: Identity and Classification

Oximum contains the compound Sildenafil Citrate, which serves as the core therapeutic agent. It is scientifically categorized as a Selective Phosphodiesterase Type 5 (PDE5) Inhibitor, a classification that indicates the drug functions by regulating a specific enzyme in the body. This classification confirms that the primary mechanism focuses on modulating enzyme activity for a focused physiological effect within circulatory processes. Oximum, as a branded Sildenafil product, shares the established efficacy of its INN, which is clinically recognized for managing conditions characterized by insufficient blood flow.

The active component, Sildenafil Citrate, is a synthetic substance produced through chemical synthesis, rather than being derived from natural sources. Oximum is a single-ingredient product, presented as an oral dosage form, typically provided as film-coated tablets, and is designed for oral administration.

General Physiological Purpose

The primary action of Oximum is to induce smooth muscle relaxation within the walls of certain blood vessels. The drug achieves this by temporarily blocking the PDE5 enzyme, which naturally breaks down the chemical messenger Cyclic Guanosine Monophosphate (cGMP). This process facilitates enhanced, sustained blood flow to targeted tissues. Scientific data confirms that preserving cGMP levels is key to the drug's therapeutic foundation, as it enables improved vascular circulation crucial for the overall purpose of the medication, which involves addressing issues related to compromised blood supply.

Regulatory References

What side effects are possible with Oximum?

Possible Side Effects and Safety Information

The official safety profile of Oximum (Sildenafil Citrate) classifies possible adverse reactions by frequency and physiological system, based on authoritative government regulatory documents.

Frequency-Classified Adverse Reactions

The most frequent effects are generally related to the drug's vasodilatory action. Regulatory data classifies side effects as follows:

Classification	Examples of Documented Effects
Very Common (1/10)	Headache
Common (1/100 and <1/10)	Dizziness, Flushing, Nasal congestion, Dyspepsia, Visual colour distortions, Vision blurred, Back pain

Less common effects include Rhinitis, Hypersensitivity reactions, Hypotension, Tachycardia, and Vomiting. The safety profile organizes effects into system-organ classes, including Nervous System Disorders, Vascular Disorders, Eye Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling documents rare but clinically significant adverse reactions. These include Myocardial Infarction, Ventricular Arrhythmia, Sudden Cardiac Death, and a prolonged erection known as Priapism. Rare ocular events like Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) are also noted.

Use of Oximum is subject to strict regulatory constraints. It is contraindicated in patients using organic nitrates or nitric oxide donors in any form due to the risk of severe hypotension. Contraindications also apply to individuals with a history of NAION, specific hereditary retinal disorders, recent stroke or myocardial infarction, and severe hepatic or renal impairment. Safety statements exist for certain populations, advising caution for patients with conditions predisposing to Priapism or significant anatomical deformation of the penis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Oximum (Sildenafil Citrate) overdose indicates that manifestations are generally an increase in the severity and frequency of known adverse events. These dose-dependent presentations may include increased instances of headache, flushing, dyspepsia, and visual color distortions.

Overdose management is exclusively symptomatic and supportive, as no specific antidote is known for Sildenafil overdose. Furthermore, regulatory labels state that renal dialysis is not expected to accelerate clearance because the active ingredient is highly bound to plasma proteins.

Required Emergency Actions

Prompt medical attention is required for specific, time-critical manifestations documented in official labeling:

Seek immediate emergency treatment if an erection persists longer than four hours (Priapism), as this can lead to potential tissue damage.
Stop taking the medication and seek prompt medical attention for the sudden occurrence of a decrease or loss of vision or a decrease or loss of hearing.

Patients with severe hepatic impairment may be at a higher risk of increased drug exposure and associated dose-related adverse effects.

Therapeutic Uses of Oximum

What Oximum Treats: Main Uses and Benefits

Oximum is commonly used across therapeutic domains, applied in conditions characterized by periods of heightened physiological stress related to compromised vascular function. The medication is considered relevant for managing Erectile Dysfunction (ED) and is applied in the long-term management of Pulmonary Arterial Hypertension (PAH).

In the context of managing Erectile Dysfunction (ED), the medication helps address symptom clusters that may become disruptive, particularly the persistent inability to achieve or maintain an erection of sufficient rigidity. The support provided assists with maintaining functional stability, and contributes to easing the overall symptom load. In the context of PAH, the medication is relevant when symptoms cluster into patterns of shortness of breath and fatigue that interfere with daily functioning. This supports patients during difficult episodes by easing distress and assisting with physical capacity.

“The support provided assists with maintaining functional stability and coping more steadily with symptom fluctuations.”

Quick Fact: Supportive Management for Key Symptom Patterns
Primary Focus	Symptom clusters related to compromised vascular-mediated function.
Symptom Management Context	Used when symptoms create noticeable physiological strain and interfere with daily functioning.
Supportive Comfort	Provides support that helps ease the overall symptom burden and contributes to improved comfort.
Usage Groups	Relevant for adult males with ED and adult and pediatric patients with PAH.

Regulatory References

Sildenafil: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Oximum

This information is based strictly on the official eligibility and non-eligibility rules documented in authoritative government regulatory sources (e.g., FDA, EMA) for the drug lumasiran (marketed as Oxlumo, consistent with the context).

Contraindications and Approved Populations

Classification	Regulatory Statement
Contraindicated Populations	Patients with a known severe hypersensitivity to lumasiran or any of the product's excipients.
Approved Age Groups	All age groups—the medicine is approved for the treatment of Primary Hyperoxaluria Type 1 (PH1) in pediatric patients (including infants) and adults.
Renal Function	Use is permitted across all severities of renal impairment, including patients on hemodialysis.

Limitations and Special Considerations

Classification	Regulatory Statement
Severe Hepatic Impairment	Use not recommended as safety and efficacy have not been established in this patient population due to lack of study data.
Pregnancy and Lactation	Use requires an individualized risk/benefit assessment by a physician due to insufficient human data. Use is not explicitly prohibited, but caution is necessary.
Treatment Restriction	Initiation and supervision of treatment must be conducted by a physician experienced in the management of PH1.

Regulatory documentation defines broad eligibility across age and kidney function, with the primary exclusion being a hypersensitivity reaction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oximum's interaction profile is documented primarily by two mechanisms: pharmacodynamic potentiation of blood pressure lowering effects and pharmacokinetic modification of its systemic exposure.

Contraindicated Combinations

The co-administration of Oximum is formally contraindicated with certain substances due to the risk of severe, life-threatening hypotension.

Organic Nitrates / Nitric Oxide Donors: All forms of organic nitrates (e.g., nitroglycerin, isosorbide dinitrate) are prohibited.
Guanylate Cyclase (GC) Stimulators: Products such as riociguat are prohibited.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substances/Categories	Regulatory Requirement
CYP3A4 Inhibition	Strong CYP3A4 inhibitors (e.g., Ritonavir, ketoconazole, erythromycin)	These substances significantly increase Oximum's plasma concentration (exposure), necessitating mandated dose restrictions.
Additive Vasodilation	Alpha-Blockers (e.g., tamsulosin, doxazosin)	May result in additive blood pressure lowering effects.

Interaction-Related Constraints

The strong pharmacokinetic interaction with Ritonavir mandates a time-based constraint: the maximum single dose of Oximum must not exceed 25 mg within a 48-hour period.

Population-specific notes indicate that clearance is reduced in patients with severe hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min), which can also lead to increased systemic exposure. Additionally, regulatory documents note that consumption of grapefruit juice may raise Oximum levels, and alcohol may contribute to additive hypotensive effects.

Mechanism of Action

The mechanism of action for Oximum (Sildenafil Citrate) is entirely focused on enzyme inhibition and the resulting modification of a critical vascular signaling pathway.

Targeted Inhibition of the PDE5 Enzyme

This domain covers the drug's molecular activity, which involves selective competitive inhibition of the Phosphodiesterase Type 5 (PDE5) enzyme. This targeted action is the crucial initial step that prevents the premature termination of a natural signaling cascade within the smooth muscle cells of the targeted vasculature.

Amplification of the Nitric Oxide-cGMP Cascade

The drug acts to potentiate the natural Nitric Oxide (NO) signaling pathway. By blocking PDE5, Oximum sustains high intracellular levels of the secondary messenger cyclic Guanosine Monophosphate (cGMP), leading to a signal for smooth muscle relaxation that is amplified and prolonged.

Modulation of Vascular Smooth Muscle Tone

The sustained cGMP levels initiate a cascade that lowers intracellular calcium concentrations, forcing the arterial smooth muscle cells to relax. This direct physiological consequence is the reduction of local vascular resistance and the resulting increase in arterial inflow to the peripheral tissues affected by this mechanism.

Dosage and Administration Information

Oximum (Sildenafil Citrate) is administered using methods and schedules that vary strictly by the condition being addressed, following official regulatory guidance. The medicine is primarily available for oral administration as tablets and is also available as an oral suspension. An intravenous (IV) injection form is approved for patients with Pulmonary Arterial Hypertension (PAH) who are temporarily unable to take the oral dose.

Indication	Dosing Regimen & Frequency	Special Instructions
Erectile Dysfunction (ED)	The standard starting dose is 50 mg orally, taken as needed, up to one hour before activity. The dose range is mathbf25 mg to mathbf100 mg, with a maximum frequency of once daily.	Dosing may be initiated at mathbf25 mg for older adults (ge 65 years) and those with severe renal or hepatic impairment. Taking the dose with food may delay the onset of activity.
Pulmonary Arterial Hypertension (PAH)	The standard dose is mathbf20 mg taken orally three times a day (TID), with doses separated by approximately four to six hours. Dosing may be adjusted to a maximum of mathbf80 mg TID.	For the TID regimen, a missed dose should be taken as soon as remembered unless close to the next scheduled dose (do not double dose).

The official protocol establishes that the appropriate administration route and form must be selected based on the indication, followed by adherence to strictly defined frequency patterns—either as needed for ED or on a fixed schedule for PAH. The protocol includes mandatory initial dose reductions for specific populations and specifies intake restrictions, such as the mandated dose limit when the medicine is co-administered with ritonavir.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oximum

Research exploring Oximum (Sildenafil Citrate) consists primarily of Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Research describes how these studies contribute to the broader evidence landscape describing observed patterns within the approved clinical situations.

Evidence for use in Erectile Dysfunction (ED)

The evidence base for this condition was established through numerous short-term RCTs, where the active substance was compared to an inactive placebo in research exploring how symptoms change over time. These studies were applied in trials examining patient-reported experiences related to functional stability and daily-life functioning in adult males. Findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level in the observed populations during the study period. Long-term, open-label extension studies have provided observations on the persistence of measured functional outcomes in patients over periods exceeding one year, although primary findings describe group patterns and are based on shorter-term, controlled data.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research for this condition, which is associated with acute or disruptive episodes and physiological strain, involved short- to intermediate-term RCTs alongside long-term extension studies. Studies monitored functional capacity and systemic or functional imbalance in adults and children with PAH.

The key outcome examined was the 6-minute walk distance (6MWD), which is used in research exploring how symptoms change over time and findings contribute to understanding symptom patterns. Multiple studies have documented outcomes related to physical discomfort and changes measured during the study period when patients were observed compared to placebo within the defined timeframe.

Understanding the Study Landscape and Evidence Gaps

The available research highlights both what is known and what remains uncertain. The highest level of evidence, the placebo-controlled trials, primarily covers outcomes related to research exploring short-term symptom changes. Consequently, long-term (multi-year) controlled data, particularly concerning the durability of effect and changes in clinical events, are mainly derived from observational settings evaluating daily-life functioning.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Oximum (FAQ)

Q: Can I stop taking Oximum once my symptoms disappear?

Regulatory guidance advises against abruptly stopping treatment with Oximum. Discontinuing the medication suddenly may carry a risk of withdrawal-like reactions or may cause symptoms to return.

Completing the full course of treatment as prescribed by a healthcare provider is generally recommended to maximize the potential for the drug's intended benefit.

Always consult your doctor or prescribing professional before making any changes to your dose or treatment schedule.

Q: Is it safe to take Oximum with alcohol?

The product label includes a precaution regarding the consumption of alcohol while taking Oximum. Regulatory information indicates that concurrent use of alcohol may increase the risk of certain side effects, such as dizziness or drowsiness, or may worsen the drug's intended effects.

Patients are generally advised to discuss alcohol consumption with their doctor or pharmacist to understand personal risks.

Q: How quickly will Oximum start working?

Clinical research suggests that the initial effects of Oximum may become noticeable within a few days of starting treatment.

However, achieving the full therapeutic benefit may take longer. Data indicates that maximal effects can occur over several weeks of continuous use, depending on the patient and the condition being treated.

It is important to follow the prescribed regimen and discuss any concerns about the timeline of effect with your healthcare provider.

How should Oximum be stored and disposed of?

How to Store and Dispose of Oximum

The storage and disposal of Oximum (Sildenafil Citrate) must adhere strictly to regulatory conditions to maintain product stability and safety.

Storage Requirement	Official Condition
Temperature	Controlled Room Temperature: 25 C (77 F), with excursions 15 C to 30 C (59 F to 86 F).
Protection	Store in the original container and protect from moisture.
Child Safety	Keep out of the sight and reach of children.

The medicine should not be stored above 30 C. Any unused or expired Oximum must be handled and disposed of in accordance with local regulatory requirements, often through a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Spain

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z